Draft synthesis: incretin receptor agonists in adolescents
Consultation on the draft synthesis of incretin receptor agonists in adolescents. The contributing evidence is small, drawn principally from the adolescent arm of the STEP programme reported in the New England Journal of Medicine in 2022, and the draft grades…
§1Consultation and window
§1.1Window
- Opened
- 7 February 2026
- Closed
- 8 April 2026
- Duration
- 60 days
- Status
- Closed — the disposition is published
- Document under consultation
- Synthesis: Incretin receptor agonists in adolescents
- Submissions received
- 16
§1.2Consultation questions
The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.
- Is the moderate certainty rating correctly drawn, given the size of the contributing evidence base?
- Is growth and pubertal development treated as an outcome in its own right rather than as a safety annex?
- Does the synthesis state clearly enough the duration over which the contributing evidence was collected, relative to the duration over which treatment would be given?
§1.3How a submission is handled
- Every submission is signed. The Institute publishes no anonymous submission.
- Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
- A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
- Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
- There is no voting, no reputation score, no reply thread and no editing after receipt.
§1.4Outcome
The synthesis was amended before ratification. Growth and pubertal development are now reported as an assessed outcome with their own certainty rating, and the gap between trial duration and expected treatment duration is stated in the abstract.
The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.